Global Antibody Partnering Terms and Agreements 2014-2020
The Global Antibody Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
- Antibody-drug conjugates
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
- Polyclonal Antibodies
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,600 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan 2014. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.
Global Antibody Partnering Terms and Agreements 2014 to 2020 provides the reader with the following key benefits:
- In-depth understanding of Antibody deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Antibody agreements with real life case studies
- Detailed access to actual Antibody contracts enter into by the leading 25 bigpharma companies
- Insight into the terms included in a Antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Antibody Partnering Terms and Agreements 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.
Global Antibody Partnering Terms and Agreements 2014 to 2020 includes:
- Trends in Antibody dealmaking in the biopharma industry since 2014
- Analysis of Antibody deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Antibody deals
- Access to over 1,600 Antibody online deal records
- The leading Antibody deals by value since 2014
- Most active Antibody dealmakers since 2014
- The leading Antibody partnering resources
In Global Antibody Partnering Terms and Agreements 2014 to 2020, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Antibody Partnering Terms and Agreements 2014 to 2020 report provides comprehensive access to available deals and contract documents for over 1,600 Antibody deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise Antibody rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Antibody Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:
- In-depth understanding of antibody deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of antibody agreements with numerous real life case studies
- Comprehensive access to over 1,600 actual antibody deals entered into by the world’s biopharma companies, together with contract documents if available
- Detailed access to actual antibody contracts enter into by the leading companies
- Identify leading antibody deals by value since 2014
- Identify the most active antibody dealmakers since 2014
- Insight into the terms included in a antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Chapter 1 – Introduction
Chapter 2 – Trends in antibody dealmaking
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates
Chapter 3 – Leading antibody deals
3.2. Top antibody deals by value
Chapter 4 – Most active antibody dealmakers
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles
Chapter 5 – Antibody contracts dealmaking directory
5.2. Antibody contracts dealmaking directory
Chapter 6 – Antibody dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 – Antibody deals by company A-Z
Appendix 2 – Antibody deals by stage of development
Appendix 3 – Antibody deals by deal type
Appendix 4 – Antibody deals by therapy area
Central Nervous System
Appendix 5 –Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Table of figures
Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2014
Figure 3: Active antibody dealmaking activity since 2014
Figure 4: Antibody partnering by deal type since 2014
Figure 5: Antibody partnering by disease type since 2014
Figure 6: Antibody deals with a headline value
Figure 7: Antibody deals with an upfront value
Figure 8: Antibody deals with a milestone value
Figure 9: Antibody deals with a royalty rate value
Figure 10: Top antibody deals by value since 2014
Figure 11: Most active antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
- $3,495: single-user
- $5,245: multi-user
- $10,495: single site license
- $17,495: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4D Pharma, 10X Genomics, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Singapore Immunology Network, Aarhus University, Aarhus University Hospital, Abbvie, Abcam, AbCellera, AbCheck, AbClon, Abcuro, Ab E Discovery, Abeome, Abilita Bio, Ab Initio, ABL Bio, Ablexis, Ablynx, AbMed, Aboundbio, Abpro, Absolute Antibody, Abveris, Abzena, Accelerate Diagnostics, Acceleron Pharma, Accord Healthcare, Aceno Biotherapeutics, Acerta Pharma, Achaogen, AC Immune, Acticor Biotech, Actinium Pharmaceuticals, Active Motif, Adagene, AdAlta, Adaptate Biotherapeutics, Adaptimmune, Adaptive Biotechnologies, ADC Therapeutics, Adimab, Adlai Nortye, Aduro BioTech, Advanced Biological Laboratories, Advanced BioScience Laboratories, Advanced Proteome Therapeutics, Advaxis, Aeglea BioTherapeutics, Aevi Genomic Medicine, AffaMed Therapeutics, Affibody, Affilogic, Affimed Therapeutics, Affinita Biotech, Affinity Biosciences, AGC Biologics, Agensys, Agenus Bio, Agilvax, AgomAb Therapeutics, AgonOx, AIMM Therapeutics, Aimmune Therapeutics, Ajinomoto, Ajinomoto Bio-Pharma Services, Akadeum Life Sciences, Akeso Biopharma, Albert Einstein College of Medicine, Alder Biopharmaceuticals, Alector, Alexion Pharmaceuticals, AlivaMab Discovery Services, Allakos, Allele Biotechnology and Pharmaceuticals, Allergan, Alligator Bioscience, Allogene Therapeutics, Alloy Therapeutics, Almac Group, Almirall, Alopexx, Alpha Cancer Technologies, Alphamab Biopharmaceuticals, Alteogen, Alvogen, Alvotech, ALX Oncology, Alytas Therapeutics, Alzheimer's Drug Discovery Foundation, Amag Pharmaceuticals, Ambrx, American Foundation for AIDS Research (amfAR), Amgen, Amneal Pharmaceuticals, Amplyx Pharmaceuticals, AnaptysBio, AnGes MG, Angiex, ANP Technologies, Antengene, Anthera Pharmaceuticals, Anthos Therapeutics, Antidote Therapeutics, Antigen Express, Antikor Biopharma, Antitope, Apceth, Apeiron Biologics, Aperion Biologics, Apexigen, Applied BioMath, APRINOIA Therapeutics, Aptevo Therapeutics, Aqualung Therapeutics, Aquila BioMedical, Aravive Biologics, Arcus Biosciences, arGEN-X, argenx, Aridis Pharmaceuticals, ARMO Biosciences, Array Biopharma, Arsanis Biosciences, Arsia Therapeutics, Artizan Biosciences, ARTMS Product, Ascenion, Ascentage Pharma, Ascletis, Aslan Pharma, Aspyrian Therapeutics, Astellas Pharma, Astex Pharmaceuticals, AstraZeneca, Asylia Therapeutics, Atara Biotherapeutics, aTen Therapeutics, Athenex, Atlab Pharma, Atlangram, Atlante Biotech, Atreca, aTyr Pharma, AusHealth, Austrian Institute of Technology, Avacta, AvantGen, Avantor, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Avillion, Avrobio, AxioMx, Aytu BioScience, Back-A-Line, Basilea Pharmaceutica, Batavia Biosciences, Bausch & Lomb, Bavarian Nordic, Baxalta, Baxter International, Bayer, Bayer Healthcare, Baylor Institute for Immunology Research, BB100, Beam Therapeutics, BeiGene, Benchwise, BerGenBio, Berkeley Lights, Beroni Group, Beth Israel Deaconess Medical Center, Bethyl Laboratories, Betta Pharmaceuticals, BHR Pharma, Biametrics, Bill and Melinda Gates Foundation, Binex, Bio-Techne, Bio-Thera Solutions, BioArctic Neuroscience, biOasis Technologies, BioAtla, Biocare Medical, Bioceros, BiocerOX Products, BioCheck, Biocon, bioCSL, Biocytogen, Biodesix, BioDuro, Bioeq IP, Biofactura, Bio Farma, Biogen, BioGenes, BioInvent, BioLegend, BiolineRX, bioLytical Laboratories, BioMarker Strategies, Biomax Informatics, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), Biomunex Pharmaceuticals, Bioncotech Therapeutics, BioNovion, BioNTech, Biooutsource, BioRap Technologies, Biosceptre International, Biotem, Biothera Pharmaceuticals, Biotheus, BioTie Therapies, BioVectra, BioVendor, Bioventix, BioWa, BioXcel, BJ Bioscience, BliNK Biomedical, BliNK Therapeutics, Bliss Biopharmaceutical, Bluebird Bio, Blue Sky Biotech, Boehringer Ingelheim, Bolt Biotherapeutics, Bpifrance, Brigham and Women's Hospital, Brii Biosciences, Bristol-Myers Squibb, Broad Institute, C-Bridge Capital, C2N Diagnostics, Caelum Biosciences, Caerus Discovery, Caliber Biotherapeutics, California Institute for Biomedical Research, California Institute for Regenerative Medicine, California Stem Cell, Calithera Biosciences, Calixar, Calypso Biotech, Canadian Institutes of Health Research, Cancer Prevention and Research Institute of Texas, Cancer Research Technology, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, CARB-X, CardiNor, Caris Life Sciences, Carlina Technologies, Catalent, CBT Pharmaceuticals, CDI Laboratories, CDR-Life, Celexion, Celgene, Celiac Disease Foundation, Celimmune, Celldex Therapeutics, Cellectis, Cellerant Therapeutics, CellforCure, Cell Marque, Cellmid, Cell Signaling Technology, Celltech, Celltrion, Celsius Therapeutics, Center for iPS Cells Research and Application, Centers for Disease Control and Prevention, Centre for Drug Research and Development (CDRD), Centre For The Commercialization Of Antibodies And Biologics, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chi-Med, Children's Hospital Boston, Chinese Academy of Sciences, Chiome Bioscience, Chromotek, Chugai Pharmaceutical, Cilag AG, Cipla, City of Hope, City of Hope Comprehensive Cancer Center, Clal Biotech, Clarity Pharmaceuticals, ClinicalRM, Clinical Trial and Consulting Services, Clinica Universidad Navarra, Clovis Oncology, CMAB Biopharma, CMC Biologics, CNA Development, Coherus Biosciences, Cold Genesys, Columbia University, Complement Pharma, Complix, Compugen, Concortis Biosystems, Conkwest, ContraFect, Cook Pharmica, Corvidia Therapeutics, Corvus Pharmaceuticals, Covalab, Covance, Creoptix, Crescendo Biologics, Cromos Pharma, Crossbeta Biosciences, Crown Bioscience, CR Pharma, CRS Bio, Crystal Bioscience, CSL, CSL Behring, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cue Biopharma, Cullinan Oncology, Curant Health, CureTech, CureVac, Curie-Cancer, Curis, Cyon Therapeutics, Cytodyn, CytomX Therapeutics, Cytovance Biologics, CYTOVIA Therapeutics, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dako, Daktari Diagnostics, Dalton Pharma Services, Dana-Farber Cancer Institute, Debiopharm, DecImmune Therapeutics, deCODE Genetics, de Duve Institute, Defense Advanced Research Projects Agency, Defyrus, Denali Therapeutics, DendroCyte, Department of Defence, Department of Defense, Department of Health and Human Services, Dermira, Diagnostic International Distribution, Diaprost, Diatheva, DiNonA, Disc Medicine, Distributed Bio, Dnastar, DNAtrix, Domain Therapeutics, Dotmatics, Dr. Falk Pharma, Dualogics, Duke-NUS Graduate Medical School Singapore, Duke University, Dyadic International, Dynavax Technologies, E25Bio, EA Pharma, Eddingpharm, eFFECTOR Therapeutics, EirGenix, Eisai, Elanco, Elektrofi, Elevation Oncology, Eleven Biotherapeutics, Eli Lilly, Elpiscience, ElsaLys Biotech, EluSys Therapeutics, EMD Millipore, EMD Serono, Emergence Therapeutics, Emergent BioSolutions, Emory University, Endocyte, enGene, Enthera, Enumeral Biomedical, Enzo Biochem, Epicypher, EpimAb Biotherapeutics, Epirus Biopharmaceuticals, EpiThany, Epivax, Epsilogen, Equillium, Erasmus University Medical Center, Essex Bio-Technology, Ethris, Eucodis Bioscience, Euprotec, Eureka Eurostars, Eureka Therapeutics, Eurofarma, Eurofins Scientific, European Commission, European Union Regional Development Fund, EUSA Pharma, Eutilex, Everest Medicines, Evotec, EVQLV, Excelimmune, Exelixis, ExpreS2ion Biotechnologies, ExScientia, F-Star, Fair Access Medicines, FairJourney Biologics, Faron Pharmaceuticals, Fate Therapeutics, Femtogenix, Ferring Pharmaceuticals, Fisher Scientific International, FIT Biotech, Five Prime Therapeutics, Florida International University, Fluidigm, FLX Bio, Food and Drug Administration (FDA), Formosa Laboratories, Forty Seven, Fosun Kite Biotechnology, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, Frontier Biotech, Fuhong Hanlin, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundacion Medina, Fusion Antibodies, Galapagos, Galaxy Biotech, Galderma, Gallus Biopharmaceuticals, GamaMabs Pharma, Genagon Therapeutics, GeneData, Genentech, GeneQuantum Healthcare, Generation Biotech, GeNeuro, Geneva Foundation, Genexine, Gen Ilac, Genmab, Genocea Biosciences, Genome and Company, Genome BC, Genome Canada, Genor Biopharma, Genprex, GenScript Biotech, GenScript ProBio, Genten Therapeutics, GenVec, George Mason University, Georgetown University, GeoVax, German Cancer Research Center, German Ministry for Education and Research, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Biological Standards Institute, Global Blood Therapeutics, Global Health Innovative Technology Fund (GHIT), Glycocept, Glycotope Biotechnology, GlycoT Therapeutics, Glykos, Glythera, Goldfinch Bio, Good Therapeutics, Goodwin Biotechnology, Gossamer Bio, GO Therapeutics, Government of Hong Kong, Gradalis, Grid Therapeutics, Gritstone Oncology, GTP Technology, Guardant Health, H-Immune, H3 Biomedicine, Hadasit Bioholdings, Hadasit Medical Research Services and Development, Halozyme Therapeutics, HanAll Pharmaceuticals, Hanmi Pharmaceutical, Harbour Antibodies, Harbour Biomed, Harpoon Therapeutics, Harvard Pilgrim Health Care, Harvard University, Harvest Capital Strategies, Hebrew University of Jerusalem, Heidelberg Pharma, Helix BioPharma, Hemogenyx, Henlius Biotech, HiFiBio, Highlight Therapeutics, Hikma Pharmaceuticals, Hisun BioRay, Hoffmann La Roche, Hong Kong University of Science & Technology, Hope Medicine, Horizon Discovery, Hospira, Hualan Genetic, Humabs BioMed, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, I-mab, i2 Pharmaceuticals, IBA Molecular Imaging, iBio, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, Iconic Therapeutics, IDBiologics, iDD Biotech, Idera Pharmaceuticals, iGEM, Igenica, IGM Biosciences, Igyxos, Iksuda Therapeutics, Illumina, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, ImClone Systems, Immatics Biotechnologies, Immucor, Immune Biosolutions, ImmuneCyte Life Sciences, Immune Design, ImmuneOncia Therapeutics, Immune Pharmaceuticals, ImmuNext, Immunitas Therapeutics, ImmunoBiochem, ImmunoBrain Checkpoint, ImmunoCellular Therapeutics, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunome, Immunomedics, Immunomic, ImmunoPrecise Antibodies, ImmunoQure, Immunovaccine, Immutep, IMPACT Therapeutics, Incyte, InDevR, InDi Molecular, Infinity Pharmaceuticals, InflamaCORE, Inhibrx, Innate Pharma, Innova Biosciences, Innovate UK, Innovative Targeting Solutions, Innovent Biologics, Inotrem, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Institut Curie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute of Biophysics, Institut Gustave Roussy, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, Intarcia Therapeutics, IntegraGen, Integral Molecular, Integrated BioTherapeutics, Intellia Therapeutics, INTELLiSTEM, Intensity Therapeutics, International AIDS Vaccine Initiative, International Consortium on Anti-Virals, Intrexon, Invenra, Invetx, InxMed, IO Biotech, Ionis Pharmaceuticals, IONTAS, Iovance Biotherapeutics, iOx Therapeutics, Ipca Laboratories, iProgen Biotech, Ipsen, IRBM, ISA Pharmaceuticals, ISIS Innovation, Isogenica, IsoTherapeutics, Israel Institute for Biological Research, iTeos Therapeutics, Izana Bioscience, Jacobson Pharma, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jasper Therapeutics, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Qyun Bio-Pharmaceutical, Jiangsu QYuns Therapeutics, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Johnson Matthey, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, JW Therapeutics, Kadmon Pharmaceuticals, KAHR Medical, Kairos Therapeutics, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kalgene Pharmaceuticals, Karolinska Institute, KBI BioPharma, Kelun-Biotech Biopharmaceutical, Kiadis Pharma, Kimberly-Clark, Kings College London, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kitov Pharma, Kleo Pharmaceuticals, Kodiak Sciences, Kolltan Pharmaceuticals, Kurma Life Sciences Partners, Kymab, Kyoto University, Kyowa Hakko Kirin, Laboratoires Thea, Laboratorios Liomont, Laboratory of Malaria Immunology and Vaccinology (LMIV), LA Cell, Laekna, La Jolla Institute for Allergy & Immunology, LakePharma, LamKap Bio Group, Lava Therapeutics, Leads Biolabs, Leaf Biopharmaceutical, Leap Therapeutics, Lee's Pharmaceutical, Lee Moffitt Cancer Center, LegoChem Biosciences, Lehigh University, Leica Biosystems, Leicester University, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, Libbs Farmaceutica, LifeArc, Ligand Pharmaceuticals, Light Chain Bioscience, Linnaeus Therapeutics, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lonza, Lpath, Ludwig-Maximilians University, Ludwig Institute for Cancer Research, Lumiphore, Lumos Pharma, Lundbeck, Lund University, Lupagen, Lupin, Lupus Therapeutics, Luye Pharma Group, Lyvgen Biopharma, Mab-Venture Biopharma, MAB Discovery, Mabion, Mablife, MabQuest, MAbSilico, Mabspace Bioscience, MabVax Therapeutics, mAbXience, Macquarie University, Macrogenics, Magenta Therapeutics, Mammoth Biosciences, Manhattan BioSolutions, Mapp Biopharmaceutical, Maryland Technology Development Corporation, Massachusetts General Hospital, MassBiologics, Maverick Therapeutics, Maxion Therapeutics, Mayo Clinic, MD Anderson Cancer Center, Medgenics, MediaPharma, Mediar Therapeutics, Medicago, Medical Research Council, Medical Research Futures Fund, Medigen Biotechnology, Medimabs, MedImmune, Mediolanum, Mediomics, Medison Pharma, Medivation, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Mersana Therapeutics, Merus, Metabiota, MicroConstants, Millennium, MilliporeSigma, MinervaX, MiniVax, Minomic, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna Therapeutics, ModiQuest Research, Moleculin Biotech, Mologen, Mologic, Momenta Pharmaceuticals, Monopar Therapeutics, Morphogenesis, MorphoSys, Morphotek, Mount Sinai Health System, Mount Sinai Medical Center, MSD, MultiCell Immunotherapeutics, Mundipharma, Muscular Dystrophy Association, Mustang Bio, Mycenax Biotech, Mylan Laboratories, Mylan Pharmaceuticals, Myriad Genetics, myTomorrows, Nabriva Therapeutics, Nanjing BioSciKin, NanoCellect Biomedica, NanoString Technologies, NantBioScience, NantCell, Nantes University, NantKwest, Nantong Jinghua Pharmaceutical, NantWorks, Nanyang Technological University, Nascent Biotech, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Centre for Research and Development, National Comprehensive Cancer Network (NCCN), National Health Research Institutes, National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute for Viral Sidease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institutes of Health, National Research Council Canada, National Research Council of Canada, National Science Foundation, Natrix Separations, Natural Sciences and Engineering Research Council of Canada, NBE Therapeutics, NCIC Clinical Trials Group, Nektar Therapeutics, NeoBiotechnologies, NeoImmuneTech, Neon Therapeutics, Neovii Pharmaceuticals, NeoX Biotech, Nerviano Medical Sciences, NETRIS Pharma, NeuClone, Neurimmune Therapeutics, Neuroblastoma and Medulloblastoma Translational Research, Newsummit Biopharma, New York Blood Center, New York University School of Medicine, Nexvet, NGM Biopharmaceuticals, Nihon Medi-Physics, NJ Bio, NJCTTQ, Nkarta Therapeutics, NKMax America, NMI Natural and Medical Sciences Institute, Nordic Nanovector, Noria Pharmaceuticals, Northern Biologics, NorthStar Medical Radioisotopes, Northway Biotechpharma, Northwestern University, NovaRock Biotherapeutics, Novartis, Novasep, Novelogics Biotechnology, Novici Biotech, NovImmune, NovoCodex, Novocure, Novogene, Novo Nordisk, Novozymes Biopharma, Noxxon Pharma, Numab, OBI Pharma, Oblique Therapeutics, Oculis, Ohio Clinical Trials Collaborative, Oligomerix, Olink Bioscience, Ology Bioservices, Olympic Protein Technologies, Omeros, OMERS, Oncobiologics, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoQuest, OncoResponse, OncoSec Medical, Oncosynergy, OncoTAb, Oncothyreon, Oncternal Therapeutics, Oncurious, One World Lab, Ono Pharmaceutical, Open Monoclonal Technology, Opthea, Oragenics, Oregon Health Sciences University, Organic Vaccines, OrImmune Bio, OSE Immunotherapeutics, Ossianix, Otsuka, Ovensa, Oxford BioTherapeutics, Oxford Genetics, Oxgene, Oxis Biotech, PacificGMP, Pall Corporation, Pamlico Biopharma, Panacea Pharmaceuticals, Pandion Therapeutics, Pangu BioPharma, Panorama Research, Pascal Biosciences, Patheon, PATH Malaria Vaccine Initiative, Paul Scherrer Institute, PDS Biotechnology, Pelican Therapeutics, Peregrine Pharmaceuticals, Perelman School of Medicine, Perrigo, Personal Genome Diagnostics, Personalis, Pfenex, Pfizer, Phanes Therapeutics, PharmAbcine, Pharmacyclics, PharmaMar, Pharmapark, PharmaPraxis, PhaseBio Pharmaceuticals, Philogen, PhosImmune, pH Pharma, Pieris, Pierre Fabre, Pionyr Immunotherapeutics, Piramal, PlantForm, Pneuma Respiratory, Polpharma, Polyplus Transfection, Polytherics, Portal Instruments, Poseida Therapeutics, Potenza Therapeutics, Precision Biologics, Prestige BioPharma, Prince William Science Accelerator, Probiodrug, ProBioGen, Procarta Biosystems, ProciseDx, Progenics Pharmaceuticals, Progenitor Cell Therapy, Prokaryotics, Prometheus Laboratories, ProMIS Neurosciences, Proteona, Prothena Biosciences, ProtoKinetix, Provenance Biopharmaceuticals, Provention Bio, pSivida, PULSALYS, Pure MHC, Purolite, Q32 Bio, QBiotics, Q Therapeutics, Quanterix, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, R-Pharm, Rakuten Medical, Ramot at Tel Aviv University, Rappaport Research Institute, RayBiotech, Redwood Bioscience, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, REMD Biotherapeutics, Rentschler Biotechnologie, Repligen, Replimune, Resonant Therapeutics, Retrogenix, Revitope, Rexahn Pharmaceuticals, Rezolute, Rheonix, Ridgeback Biotherapeutics, River Vision Development, Roche, Rockefeller University, Rocket Pharmaceuticals, Rockland Immunochemicals, Roivant Sciences, Roswell Park Cancer Institute, Royalty Pharma, RuiYi, Rutgers University, SAB Biotherapeutics, SAB Therapeutics, Sahlgrenska University Hospital, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanford Burnham Institute, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Sanquin Blood Supply Foundation, Santen Pharmaceutical, Sarah Cannon Research Institute, SATT Sud-Est, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), SaudiVax, Scandion Oncology, Scholar Rock, Schrodinger, SciCrunch, Scienion, Scientist.com, Sciex, Scil Proteins, Scripps Research Institute, Sea Lane Biotechnologies, Seattle Biomed, Seattle Children's Hospital, Seattle Genetics, Sedia Biosciences, Seismic Bio, Selecxine, Selexis, SELLAS Life Sciences Group, Seneca Biopharma, Sensei Biotherapeutics, Serono, Serum Institute of India, Seven and Eight Biopharmaceuticals, Sevion Therapeutics, SFJ Pharmaceuticals, Shandong Boan Biological Technology, Shandong Fontacea Pharmaceutical, Shanghai Miracogen, ShanghaiTech University, Shenogen Pharma, Shenzhen Arimab Biopharmaceuticals, Shenzhen Chipscreen Biosciences, Shenzhen Hepalink Pharmaceutical, Shire Laboratories, Shire Pharmaceuticals, Siamab Therapeutics, Siemens Healthineers, Sigma-Aldrich, SillaJen, Simcere Pharmaceuticals, Simon Fraser University, Singlomics Biopharmaceuticals, Sinobioway, Sirnaomics, Siteman Cancer Center, Small Business Innovation Research, SmartPharm Therapeutics, Solentim, Sorrento Therapeutics, Sosei Heptares, SOTIO, Specialized Medical Services-oncology, Spotlight Innovation, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, STADA Arzneimittel, Stand Up To Cancer, Stanford University, Staten Biotechnology, STC Biologics, STCube, Stony Brook University, Strata Oncology, Strox Biopharmaceuticals, Sud Investments, Sunnybrook Research Institute, Sun Pharmaceutical, Surface Oncology, Surrozen, Sutro Biopharma, Swedish Orphan, Swedish Orphan Biovitrum, Swiss Federal Institute of Technology ETH Zurich, Swixx Biopharma, Symphogen, Synaffix, Syndax Pharmaceuticals, Synergys Biotherapeutics, Synlogic, Synthon, Syracuse Biopharma, Syracuse University, Syros Pharmaceuticals, Systimmune, Taiho, TaiMed, Taiwan Ministry of Economic Affairs, Takeda Pharmaceutical, Talem Therapeutics, Tanabe Research Laboratories, Targovax, TARIS Biomedical, Tavotek Biotherapeutics, Technical University of Denmark (DTU), Technology Strategy Board (UK), Teijin, Tekon Biotech, Telix Pharmaceuticals, Temple University, TeneoBio, TeneoOne, Tesaro, Tessa Therapeutics, Tetragenetics, TetraLogic Pharmaceuticals, Teva Pharmaceutical Industries, TFF Pharmaceuticals, TG Therapeutics, The International AIDS Vaccine Initiative, Theraclone Sciences, Theradiag, Theranyx, Theravectys, Thermo Fisher Scientific, ThioLogics, Thomas Jefferson University, ThromboGenics, Tianjin University, Tikcro Technologies, Tillotts Pharma, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, Tonbo Biosciences, TONIX Pharmaceuticals, TopAlliance Biosciences, Topas Therapeutics, Torch Biosciences, Torque Therapeutics, TOT BIOPHARM, Totient, TPG Capital, TRACON Pharmaceuticals, TransBio, Transcenta, Transgene, TransPerfect Life Sciences, Transporin, Trellis Bioscience, Tri-Institutional Therapeutics Discovery Institute, Trianni, Trieza Therapeutics, TRIGR Therapeutics, Trio Pharmaceuticals, Triphase Accelerator, TrueBinding, Tsinghua University, Tubulis, TuHURA Biopharma, Turgut Ilaclari, Twist Bioscience, UbiVac, UCB, Ultragenyx Pharmaceuticals, Uman Diagnostics, UMass Memorial Medical Center, Unilife, Universite Claude Bernard Lyon, University City Science Center, University College London, University Hospital Heidelberg, University of Alabama at Birmingham, University of Bergen, University of Birmingham, University of British Columbia, University of Buffalo, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cologne, University of Edinburgh, University of Florida, University of Heidelberg, University of Illinois at Chicago, University of Manchester, University of Maryland, University of Maryland Baltimore, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Minnesota, University of Natural Resources and Life Sciences, University of New Mexico, University of North Texas Health Science Center, University of Nottingham, University of Oxford, University of Pennsylvania, University of Rochester, University of Southampton, University of Texas, University of Tubingen, University of Turku, University of Washington, University of Wisconsin Carbone Cancer Center (UWCCC), University of Zurich, University Paris Diderot, Unum Therapeutics, Uppsala University, UroGen Pharma, US Army, US Army Medical Research Institute of Infectious Diseases, US Government, Utrecht University, Vaccinex, Valeant Pharmaceuticals, Valneva, Vanderbilt University, Vaximm, Vcell Healthcare, Vect-Horus, Vedanta Biosciences, Velabs Therapeutics, Velo Bio, Velocity Pharmaceutical Development, venBio, Ventana Medical Systems, Verastem, Verseau Therapeutics, VIB, Vical, Viela Bio, Vincera Pharma, Vinnova, ViralClear Pharmaceuticals, Viralytics, Virbac, Vir Biotechnology, Viroclinics Biosciences, Visterra, Vitaeris, Vitesse Biologics, Vizient, Voyager Therapeutics, VU University Amsterdam, Vyera Pharmaceuticals, Vyriad, Wacker Biotech, Washington University in St Louis, Weill Cornell Medical College, Wellcome Trust, WEP Clinical, Wilex, WindMIL Therapeutics, Wisconsin Alumni Research Foundation, Wistar Institute, World Health Organization, WuXi Biologics, Wuxi Shuangliang Biotechnology, XBiotech, Xbrane Bioscience, xCella Biosciences, Xencor, Xoma, Y-Biologics, Yale University, Yas Holding, Yeda Research and Development Company, Yissum Research Development, YL Biologics, Yoshindo, ZAI Laboratory, Zebra Biologics, Zenoaq, Zenyaku Kogyo, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zoetis, Zydus Cadila, Zymeworks, ZyVersa Therapeutics
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.